Last reviewed · How we verify
Non-quinolone antibiotic
Non-quinolone antibiotics inhibit bacterial protein synthesis or cell wall formation through mechanisms distinct from fluoroquinolone drugs.
Non-quinolone antibiotics inhibit bacterial protein synthesis or cell wall formation through mechanisms distinct from fluoroquinolone drugs. Used for Bacterial infections (specific indication unknown without drug identity).
At a glance
| Generic name | Non-quinolone antibiotic |
|---|---|
| Sponsor | Bayer |
| Drug class | Non-quinolone antibiotic |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This category encompasses multiple antibiotic classes (such as beta-lactams, macrolides, tetracyclines, aminoglycosides, and others) that work through diverse mechanisms including inhibition of bacterial ribosomal protein synthesis, disruption of cell wall integrity, or interference with nucleic acid metabolism. The defining characteristic is that they are not fluoroquinolones, which target bacterial DNA gyrase and topoisomerase IV.
Approved indications
- Bacterial infections (specific indication unknown without drug identity)
Common side effects
- Gastrointestinal disturbance
- Hypersensitivity reaction
- Photosensitivity (if tetracycline-class)
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Role of Prophylactic Postoperative Antibiotics in HoLEP (PHASE4)
- Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer (PHASE2)
- Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial (PHASE3)
- Early Antibiotics After Aspiration in ICU Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |